
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Intrinsic Value
The intrinsic value of one
BCLI
stock under the Base Case scenario is
0.0559
USD.
Compared to the current market price of 1.1136 USD,
Brainstorm Cell Therapeutics Inc
is
Overvalued by 95%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Brainstorm Cell Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Brainstorm Cell Therapeutics Inc
Balance Sheet Decomposition
Brainstorm Cell Therapeutics Inc
Current Assets | 2.3m |
Cash & Short-Term Investments | 1.6m |
Receivables | 67k |
Other Current Assets | 621k |
Non-Current Assets | 1.2m |
PP&E | 1m |
Other Non-Current Assets | 204k |
Free Cash Flow Analysis
Brainstorm Cell Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Brainstorm Cell Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-12.3m
USD
|
Operating Income
|
-12.3m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
-11.1m
USD
|
BCLI Profitability Score
Profitability Due Diligence
Brainstorm Cell Therapeutics Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Score
Brainstorm Cell Therapeutics Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
BCLI Solvency Score
Solvency Due Diligence
Brainstorm Cell Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Score
Brainstorm Cell Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCLI Price Targets Summary
Brainstorm Cell Therapeutics Inc
Dividends
Current shareholder yield for BCLI is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BCLI
stock under the Base Case scenario is
0.0559
USD.
Compared to the current market price of 1.1136 USD,
Brainstorm Cell Therapeutics Inc
is
Overvalued by 95%.